Mitigating Radiation-Related Immune Problems with PrC-210
Official title: Mitigation of Radiation Induced Immune Dysfunction by PrC-210 Treatment
Funded at Henry M. Jackson Fdn for the Adv Mil/med · NIH-11358373 · Data updated 2026-11-12
A new CBRN countermeasure, PrC-210, is being studied in animals to help the immune system recover after severe radiation exposure.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | August 17, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $349,970 |
| NIH project number | 5U01AI170033-05 |
| Project ID | NIH-11358373 on NIH RePORTER |
Who could benefit from this research
✓Could help
N/A for this animal study; potential future patients would be individuals at risk of or exposed to high-dose radiation.
✕Less likely to help
No direct patient benefit until later translational steps are completed.
What this research studies
This project tests whether giving PrC-210, a protective drug, after a high radiation dose can improve survival and protect immune and gut health in mice. Researchers will optimize how the drug is delivered systemically 24 hours after radiation and look for clues about how it helps the immune system and gut tissues recover. The work builds on earlier findings showing increased survival with post-exposure treatment and aims to translate those findings into clearer mechanisms and better dosing strategies. While the study is in animals, its goal is to inform potential countermeasures for people who experience serious radiation exposure.
Why it matters
Potential benefit: If successful, the approach could lead to a practical treatment to improve survival and immune function after radiation exposure.
How similar studies have gone: Earlier mouse studies showed a meaningful survival benefit with PrC-210 after radiation exposure.
Where this research is happening
-
Henry M. Jackson Fdn for the Adv Mil/med
Bethesda, United States Active
Researchers
- Principal investigator: Kumar, Vidya P. — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Kumar, Vidya P.
Related research
Other NIH-funded projects on the same topics.
-
Cooperation partners of SETBP1 in AML development
This grant explores how SETBP1 and AF9 (MLLT3) work together to drive acute myeloid leukemia and whether targeting related epigenetic regulators could help treat aggressive CK-AML.
-
U.S. Military HIV Research Program Clinical Trials Unit expansion
A nationwide network of clinical trial sites is being expanded to test HIV prevention and treatment approaches through DAIDS-supported trials.
-
Novel protein biomarkers of chronic pain in adults using a pain registry biobank
A study in adults with chronic pain will look for new protein biomarkers in blood samples to understand better why pain persists and how to improve treatment.
-
Tailored antibody cures for HIV using AI and vaccines
A study to design personalized antibody-based strategies to achieve HIV remission, using lab experiments and computer models to tailor vaccines or antibody treatments to individuals or small groups.
-
Understanding how antibody protection works using 3D protein structures
Researchers will build a 3D-based method to see which viral features relate to prevention by antibodies, using data from people in HIV vaccine and monoclonal antibody trials.
-
Military HIV Clinical Network
This program runs HIV and TB prevention and treatment clinical studies for adults in military-associated and high-HIV-burden communities.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.